|
End-of-day quote
Borsa Italiana
2026-09-22
|
5-day change | 1st Jan Change | ||
| 74.15 EUR | -0.56% |
|
-0.34% | -10.71% |
| 09-24 | US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes | RE |
| 09-23 | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
| Market Cap | 86.38B 98.2B 81.43B 74.29B 139B 9,427B 140B 977B 379B 4,798B 369B 361B 15,612B | P/E 2026 * |
11.5x | P/E 2027 * | 10x |
|---|---|---|---|---|---|
| Enterprise Value | 97.84B 111B 92.24B 84.15B 157B 10,678B 159B 1,107B 429B 5,434B 418B 409B 17,684B | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | 1.87x |
| Free-Float |
88.34% | Yield 2026 * |
5.9% | Yield 2027 * | 6.24% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| SAN | Real-time | |
CBOE
| SAN | Real-time | |
|
London S.E.
| 0O59 | Delayed | |
|
Xetra
| SNW | Delayed | |
|
Tradegate
| SNW | Real-time | |
|
Börse Stuttgart
| SNW | Delayed | |
|
Deutsche Boerse AG
| SNW | Delayed | |
|
Boerse Muenchen
| SNW | Real-time | |
|
Borsa Italiana
| 1SAN | End-of-day quote | |
|
Mexican S.E.
| SAN1 N | End-of-day quote | |
|
Wiener Boerse
| SANO | End-of-day quote | |
|
OTC Markets
| SNYNF | Delayed | |
|
Bulgaria S.E.
| SNW | End-of-day quote | |
|
Swiss Exchange
| SAN | Delayed | |
|
CBOE
| 0O59 | Real-time |
Last Transcript: Sanofi
| 1 day | -0.56% | ||
| 1 week | -0.34% | ||
| Current month | -3.38% | ||
| 1 month | -6.09% | ||
| 3 months | +0.82% | ||
| 6 months | -3.64% | ||
| Current year | -10.71% |
| 1 week | 72.12 |  | 75.3 |
| 1 month | 72.12 | | 80 |
| Current year | 71.27 | | 84.9 |
| 1 year | 71.27 | | 90.78 |
| 3 years | 71.27 | | 111 |
| 5 years | 71.27 | | 111 |
| 10 years | 63.15 | | 111 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | -0.34% | - | - | 99.8B | |
| +2.68% | +2.56% | +59.32% | +114.68% | 1,026B | |
| +0.56% | +0.17% | +53.19% | +68.65% | 649B | |
| +0.02% | +0.42% | +20.51% | +73.58% | 468B | |
| +0.06% | +0.25% | +37.03% | +45.71% | 352B | |
| +1.16% | +4.10% | +21.99% | +29.39% | 271B | |
| -0.24% | +2.18% | +10.14% | +12.26% | 256B | |
| -0.01% | +6.91% | +45.42% | +51.68% | 220B | |
| -1.11% | -0.80% | +31.69% | +99.56% | 188B | |
| +0.30% | -7.19% | -32.43% | -60.56% | 170B | |
| Average | +0.01% | +1.29% | +27.43% | +48.33% | 399.9B | |
| Weighted average by Cap. | +0.11% | +1.48% | +38.06% | +67.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.65B 54.17B 44.92B 40.98B 76.64B 5,200B 77.24B 539B 209B 2,646B 203B 199B 8,612B | 50.64B 57.58B 47.74B 43.56B 81.46B 5,527B 82.09B 573B 222B 2,813B 216B 211B 9,153B |
| Net income | 7.48B 8.5B 7.05B 6.43B 12.03B 816B 12.12B 84.6B 32.78B 415B 31.92B 31.23B 1,352B | 8.89B 10.1B 8.38B 7.64B 14.29B 970B 14.4B 101B 38.95B 494B 37.93B 37.11B 1,606B |
| Net Debt | 11.46B 13.03B 10.81B 9.86B 18.44B 1,251B 18.58B 130B 50.25B 637B 48.93B 47.87B 2,072B | 8.34B 9.48B 7.86B 7.17B 13.41B 910B 13.51B 94.3B 36.54B 463B 35.58B 34.81B 1,507B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-24 | €72.12 | -1.48% | 1,864 |
| 26-09-23 | €73.20 | -1.28% | 3,911 |
| 26-09-22 | €74.15 | -0.56% | 717 |
| 26-09-21 | €74.57 | +0.66% | 680 |
| 26-09-18 | €74.08 | -1.41% | 1,016 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- 1SAN Stock
Select your edition
All financial news and data tailored to specific country editions
